By Melanie Senior
Partners—especially those with products--are increasingly important to Big Pharma. That's clear from the growing number, and value, of product-focused deals...
The Winners Post-Vioxx: Merck's Product-Focused Biotechs
Listen to this article
Vioxx's withdrawal late in September just made partnering success even more critical to Merck & Co. With a $2.55 billion gap in revenues from Vioxx and having lost two Phase III development products late in 2003, the company now leans more heavily still on external R&D success. That's good news for Merck's partners--particularly those with products.
Candid conversations with C-suite leaders.
More from Business Strategy
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
• By
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
• By
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
More from In Vivo
• By
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
• By
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
